Form 13-F position report

EIGER BIOPHARMACEUTICALS INC C

Reported by MORGAN STANLEY

EIGR CUSIP 28249U105 Manager CIK 0000895421

Reported 896,867 shares, down 525,411 (36.9%) from the prior quarter.

Reported value -52.1%; share count -36.9% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 896,867 Quarter-end amount reported
Reported value $5,650,000 Fair value at quarter end
Consecutive quarters held 26 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2179000
2022-03-31 11805000
2022-06-30 5650000
2022-09-30 3702000
2022-12-31 978194
2023-03-31 65831
2023-06-30 42724
2023-09-30 8997
2023-12-31 3101
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for EIGER BIOPHARMACEUTICALS INC C held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -13,812 (-100.0%) 0 $0 2024-05-15
Q4 2023 Reduced 13,812 -15,684 (-53.2%) < 0.01% $3,101 2024-02-13
Q3 2023 Reduced 29,496 -31,192 (-51.4%) < 0.01% $8,997 2023-11-15
Q2 2023 Reduced 60,688 -12,711 (-17.3%) < 0.01% $42,724 2023-08-14
Q1 2023 Reduced 73,399 -755,578 (-91.1%) < 0.01% $65,831 2023-05-15
Q4 2022 Added 828,977 +337,191 (68.6%) < 0.01% $978,194 2023-02-14
Q3 2022 Reduced 491,786 -405,081 (-45.2%) < 0.01% $3,702,000 2022-11-14
Q2 2022 Reduced 896,867 -525,411 (-36.9%) < 0.01% $5,650,000 2022-08-15
Q1 2022 Added 1,422,278 +1,002,479 (238.8%) < 0.01% $11,805,000 2022-05-13
Q4 2021 Added 419,799 +310,725 (284.9%) < 0.01% $2,179,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

104 managers reported EIGER BIOPHARMACEUTICALS INC C for Q2 2022.

Managers reporting EIGER BIOPHARMACEUTICALS INC C in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
AMERIPRISE FINANCIAL INC Added 7,675,577 +180,514 0.02% $48,356,000 8 qtrs
683 Capital Management LLC Added 3,865,000 +490,000 1.72% $24,350,000 18 qtrs
BlackRock Inc Added 2,756,733 +312,469 < 0.01% $17,367,000 25 qtrs
VANGUARD GROUP INC Added 1,919,336 +230,093 < 0.01% $12,092,000 26 qtrs
ADAGE CAPITAL PARTNERS GP L L C Reduced 1,050,000 -650,000 0.02% $6,615,000 2 qtrs
MORGAN STANLEY This report Reduced 896,867 -525,411 < 0.01% $5,650,000 26 qtrs
Soleus Capital Management L P Added 846,000 +63,000 0.83% $5,330,000 11 qtrs
STATE STREET CORPORATION Added 702,350 +148,035 < 0.01% $4,425,000 14 qtrs
Knoll Capital Management LLC Unchanged 694,232 0 2.5% $4,374,000 18 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 691,469 +55,898 < 0.01% $4,356,000 25 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
893,135
Shared
0
None
3,732

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.